{"id":532006,"date":"2021-02-26T20:44:01","date_gmt":"2021-02-26T20:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=532006"},"modified":"2021-02-26T20:44:01","modified_gmt":"2021-02-26T20:44:01","slug":"chronic-hand-eczema-market-market-insights-and-market-trend-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hand-eczema-market-market-insights-and-market-trend-by-delveinsight_532006.html","title":{"rendered":"Chronic Hand Eczema Market: Market Insights and Market Trend by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1614323094.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Hand Eczema Market: Market Insights and Market Trend by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1614323094.png\" alt=\"Chronic Hand Eczema Market: Market Insights and Market Trend by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hand-eczema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Chronic Hand Eczema Market<\/strong><\/a><\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder affecting the hands. In a substantial number of patients, HE can develop into a chronic condition that remain active even after avoidance of contact with potentially damaging allergens and\/or irritants. Chronic Hand Eczema (CHE) has been defined as either a long-lasting, relapsing course of HE, or HE unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months or the recurrence of symptoms two or more times within a year despite treatment. It seems more relevant to define CHE as an anatomoclinic syndrome with multifactorial origin.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The key players elaborated in the <strong>Chronic Hand Eczema Market report includes <\/strong>Stiefel Laboratories, Japan Tobacco, Asana Biosciences etc<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Free Report Sample- <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-hand-eczema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/chronic-hand-eczema-market <\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Hand eczema is an inflammatory skin disorder, clinically characterized by erythema, infiltration, hyperkeratosis, oedema, and vesicles. Secondary signs may be scaling, hyperkeratotic areas, fissures, erosions, and bacterial infections, chiefly with Staphylococcus aureus. Important symptoms are itching and pain if there are fissures. Erythema, oedema and vesicles are characteristic of acute eczema, whereas infiltration, hyperkeratosis and fissures are seen in chronic eczema.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hand-eczema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Chronic Hand Eczema Market Key Companies<\/strong><\/a><\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>Stiefel Laboratories,<\/li>\n<li>Japan Tobacco,<\/li>\n<li>Asana Biosciences etc<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Hand Eczema Market Key Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>11 Years Forecast<\/li>\n<li>7MM Coverage<\/li>\n<li><strong>Chronic Hand Eczema <\/strong>Epidemiology Segmentation<\/li>\n<li>Key Cross Competition<\/li>\n<li>Highly Analyzed Market<\/li>\n<li>Drugs Uptake<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Browse Report Overview<\/strong>&#8211; <span style=\"text-decoration: underline;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-hand-eczema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/bacterial-vaginosis-market<\/a><\/strong><\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Global Chronic Hand Eczema Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">As per DelveInsight assessments, the therapeutic market of Chronic Hand Eczema (CHE) in seven major markets was found to be USD 1,226.71 million in 2017. The United States accounts for the largest CHE market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.<\/p>\n<p style=\"text-align: justify;\">Among the 5 European countries, Germany had the highest prevalent population of Chronic Hand Eczema, followed by France, the United Kingdom, Italy, and Spain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Hand Eczema Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment of HE must take into account the general principles of treatment of stage-appropriate therapy, disease etiology (atopic, allergic, and irritant), acuteness (acute vs. chronic eczema), morphology (redness, scaling, lichenification, blistering, hyperkeratosis, rhagades, etc.) and location (dorsal aspects of hands, interdigital spaces, palms). Acute HE should be treated quickly and consequently to avoid the development of chronic HE. Topical corticosteroids, together with emollients, are the most effective treatment to control an acute flare of CHE..<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Hand Eczema Geography Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The United States<\/li>\n<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/li>\n<li>Japan<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive summary<\/p>\n<p style=\"text-align: justify;\">3. Chronic Hand Eczema: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">5. Organizations<\/p>\n<p style=\"text-align: justify;\">6. Chronic Hand Eczema: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Total Prevalent Cases of Chronic Hand Eczema in 7MM<\/p>\n<p style=\"text-align: justify;\">9. United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">10. EU5 Epidemiology<\/p>\n<p style=\"text-align: justify;\">11. Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">12. Prevention and Treatment of Chronic Hand Eczema<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">15. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">16. Chronic Hand Eczema: 7MM Market Analysis<\/p>\n<p style=\"text-align: justify;\">17. United States: Market Outlook<\/p>\n<p style=\"text-align: justify;\">18. EU-5 countries: Market Outlook<\/p>\n<p style=\"text-align: justify;\">19. Japan Market Outlook<\/p>\n<p style=\"text-align: justify;\">20. Reimbursement policies<\/p>\n<p style=\"text-align: justify;\">21. Market Drivers<\/p>\n<p style=\"text-align: justify;\">22. Market Barriers<\/p>\n<p style=\"text-align: justify;\">23. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">24. Case Report<\/p>\n<p style=\"text-align: justify;\">25. KOL Views<\/p>\n<p style=\"text-align: justify;\">26. Appendix<\/p>\n<p style=\"text-align: justify;\">27. Report Methodology<\/p>\n<p style=\"text-align: justify;\">28. <strong>DelveInsight <\/strong>Capabilities<\/p>\n<p style=\"text-align: justify;\">29. Disclaimer<\/p>\n<p style=\"text-align: justify;\">30. About <strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Enquire about<\/strong> <strong>Chronic Hand Eczema Market Report-<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-hand-eczema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-hand-eczema-market &nbsp;<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight<\/strong> is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>CONTACT US:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Shruti Thakur<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>info@delveinsight.com <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>+91-9650213330<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-hand-eczema-market-market-insights-and-market-trend-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-hand-eczema-market-market-insights-and-market-trend-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; DelveInsight has launched a new report on Chronic Hand Eczema Market &nbsp; Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder affecting the hands. In a substantial number of patients, HE can &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hand-eczema-market-market-insights-and-market-trend-by-delveinsight_532006.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,406,423],"tags":[],"class_list":["post-532006","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=532006"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532006\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=532006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=532006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=532006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}